StockData
Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc. (NTLA) company profile

NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/307% above fair value
$9.78−0.08 (-0.81%)

Close on Nov 17, 2026Market cap $1.37BP/E –Yield –

About Intellia Therapeutics

In Vitro & In Vivo Diagnostic Substances, SIC 2835

Intellia Therapeutics is a biopharmaceutical company that develops treatments utilizing CRISPR gene editing, lipid nanoparticles, and oligonucleotide technologies to address severe genetic diseases. Its lead investigational product candidates are lonvoguran ziclumeran, designed for hereditary angioedema, and nexiguran ziclumeran, developed for transthyretin amyloidosis. Both therapies are designed as one-time intravenous infusions. The company also develops preclinical and clinical-stage programs in cellular therapies, including universal CAR-T cell treatments. Its therapies target individuals diagnosed with rare and life-threatening conditions, while the business works alongside healthcare prescribers, clinical institutions, and pharmaceutical collaboration partners such as Regeneron.

Operationally, the company conducts international Phase 3 clinical trials, including studies that have enrolled dozens to hundreds of patients across multiple trial sites. Its development activities and commercial infrastructure focus primarily on the United States, alongside regulatory engagements in the European Union and the United Kingdom. The provided text does not identify the location of the company’s corporate headquarters.

Summary of the business section of Intellia Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Intellia Therapeutics, Inc.
Founded
2014
Headquarters
Cambridge, MA
Address
400 Technology Square, Suite 100
Phone
(857) 285-6200
Employees
377, Dec 31, 2025
Industry
In Vitro & In Vivo Diagnostic Substances
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, Boston, Massachusetts

Stock & identifiers

Ticker
NTLA
Exchange
Nasdaq
IPO date
May 6, 2016
Shares outstanding
140M, Jul 31, 2026
Public float
$869.49M, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1652130
CUSIP
45826J105
ISIN
US45826J1051
FIGI
BBG007KC7PB0
Share class FIGI
BBG007KC7PC9
LEI
5493002T5BCPE5DZC723
EIN
36-4785571

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
John M. LeonardPresident and CEO, Director1,196,479
Jing L. MarantzEVP, Chief Medical Officer199,822
Michael P. DubeVP, Chief Accounting Officer65,022
Edward J. Dulac IIIEVP, Chief Financial Officer148,175
Birgit C. SchultesEVP, Chief Scientific Officer137,733
James BastaEVP, General Counsel156,794
David LebwohlEVP, Chief Medical Officer131,192
Eliana ClarkEVP, Chief Technical Officer93,864
Derek HicksEVP, Chief Business Officer59,878
Laura Sepp-LorenzinoEVP, Chief Scientific Officer77,388
Brian GoffDirector32,609
Muna BhanjiDirector36,403
Georgia KerestyDirector41,083
Fred E. CohenDirector216,653
Frank VerwielDirector35,148
Jesse GoodmanDirector33,559
William J. ChaseDirector143,893

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$5.06M$3.24M$1.93M$17$187
FY2024$15.33M$353.49K$4.74M$21$154
FY2023$11.66M$8.32M$4.06M$56$119
FY2022$10.10M-$14.07M$3.92M$64$82
FY2021$9.77M$37.78M$6.99M$217$122
FY2020$3.64M$19.28M$1.76M$371$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsOtherTotalvs. prior year
John M. Leonard
President, Chief Executive Officer
$708.00K$529.23K$2.44M$1.36M$26.43K$5.06M-67%
Edward J. Dulac III
Executive Vice President, Chief Financial Officer and Treasurer
$526.00K$271.00K$848.18K$466.61K$56.72K$2.17M-68%
James Basta
Executive Vice President, General Counsel and Corporate Secretary
$494.00K$227.24K$718.80K$395.43K$11.13K$1.85M-62%
David Lebwohl
Executive Vice President, Chief Medical Officer
$536.00K$234.23K$776.30K$427.06K$11.13K$1.98M-64%
Birgit Schultes
Executive Vice President, Chief Scientific Officer
$475.00K$207.58K$675.67K$371.70K$10.14K$1.74M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
May 6, 2016
Offer price
$18.00
Securities offered
6,000,000
Gross proceeds
$108.00M
Exchange
Nasdaq
First trading day
May 6, 2016
First-day close
$22.10+22.8%
Lock-up ends (est.)
Nov 2, 2016

“The initial public offering price of our common stock is $18.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of February 13, 2026, we had 377 full-time employees, 263 of whom were primarily engaged in research and development activities and 106 of whom have an M.D.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?